HSCS · XBRL financial data

HeartSciences financial statements, every fiscal year

The same tables from 4 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (HSCS's year ends in late June)

In thousands of dollars	FY 2023Apr 30, 2023	FY 2024Apr 30, 2024	FY 2025Apr 30, 2025	FY 2026†Jun 30, 2026
Revenue from contracts with customers	5	19	4	—
Cost of revenue	3	6	2	—
Gross profit	2	13	2	—
Research and development	2,461	2,879	4,386	—
Selling, general and administrative	3,654	3,440	3,969	—
Total operating expenses	6,115	6,318	8,355	—
Operating income (loss)	(6,113)	(6,306)	(8,353)	—
Interest expense	243	354	500	—
Other income (expense)	—	—	88	—
Income tax expense (benefit)	—	—	0	—
Net income (loss)	(6,354)	(6,605)	(8,765)	—
Earnings per share, basic‡ USD per share	(80.00)	(19.00)	(9.34)	—
Earnings per share, diluted‡ USD per share	(80.00)	(19.00)	(9.34)	—
Weighted average shares, basic‡ thousands of shares	80	353	938	—
Weighted average shares, diluted‡ thousands of shares	80	353	938	—

‡ Per-share figures and share counts are adjusted for the 1-for-100 stock split (October 2025); filings made before it reported them unadjusted.
† Share count changed about 2x in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (HSCS's year ends in late June)

In thousands of dollars	FY 2023Apr 30, 2023	FY 2024Apr 30, 2024	FY 2025Apr 30, 2025	FY 2026†Jun 30, 2026
Cash and cash equivalents	1,660	5,808	1,098	1,657
Accounts receivable	—	—	4	0
Inventory	676	629	650	656
Total current assets	2,697	7,354	2,171	2,583
Property and equipment, net	61	98	64	39
Right-of-use asset	529	462	372	268
Total assets	3,287	9,503	4,223	5,263
Accounts payable	631	448	319	318
Accrued liabilities	623	398	506	—
Total current liabilities	1,833	1,752	3,703	4,861
Lease liability, non-current	536	434	315	176
Total liabilities	3,057	2,186	4,018	5,037
Accumulated deficit	(60,757)	(67,362)	(76,128)	(85,270)
Total stockholders' equity	231	7,317	205	226
Total liabilities and equity	3,287	9,503	4,223	5,263
Common shares outstanding (cover page)‡ thousands of shares	104	856	1,934	3,899

‡ Per-share figures and share counts are adjusted for the 1-for-100 stock split (October 2025); filings made before it reported them unadjusted.
† Share count changed about 2x in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (HSCS's year ends in late June)

In thousands of dollars	FY 2023Apr 30, 2023	FY 2024Apr 30, 2024	FY 2025Apr 30, 2025	FY 2026†Jun 30, 2026
Net income (loss)	(6,354)	(6,605)	(8,765)	—
Stock-based compensation	248	405	250	—
Net cash from operating activities	(5,774)	(6,070)	(7,413)	—
Purchases of property and equipment	18	64	3	—
Net cash from investing activities	(18)	(125)	(30)	—
Proceeds from issuing common stock	5,195	—	1,148	—
Net cash from financing activities	6,534	10,343	2,734	—
Net change in cash	742	4,147	(4,710)	—

† Share count changed about 2x in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 6199 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 6199 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
HeartSciences	30	2.1	(1,319)	4.8M	0.0 quarters	Q1 FY27 10-QJul 31, 2026
Applied Dna Sciences	3,761	not reported	not reported	6.2M	—	Q3 FY26 10-QJun 30, 2026
ZeroStack	2,640	13,658	1,373*	17.5M	—	Q2 FY26 10-QJun 30, 2026
Marblegate Capital	7,312	16,681	(5,202)*	73.9M	1.4 quarters	Q2 FY26 10-QJun 30, 2026
Marygold Companies	2,880	6,925*	129*	42.7M	—	Q4 FY26 10-KJun 30, 2026
Beneficient	5,582	12,165	(4,105)	not reported	1.4 quarters	Q1 FY27 10-QJun 30, 2026
Soluna Holdings	113,364	15,060	(5,183)*	244.6M	21.9 quarters	Q2 FY26 10-QJun 30, 2026
FG Nexus	24,923	242	(4,543)*	5.1M	5.5 quarters	Q2 FY26 10-QJun 30, 2026
Axe Compute	21,906	not reported	not reported	11.6M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.